CI 1012

Drug Profile

CI 1012

Alternative Names: PD 159206

Latest Information Update: 29 Dec 1998

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer National Institutes of Health (USA); Pfizer
  • Class Antivirals; Benzamides
  • Mechanism of Action HIV zinc finger inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 29 Dec 1998 Discontinued-II for HIV infections treatment in USA (PO)
  • 05 Mar 1997 Phase-II clinical trials for HIV infections treatment in USA (PO)
  • 08 Aug 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top